News & Updates
Showing Multidisciplinary articles
Showing
Medication risks an acceptable trade-off for cure of IBS symptoms
Patients with irritable bowel syndrome (IBS) are willing to take on significant medication risks in exchange for a permanent cure of their symptoms, a study has found.
Medication risks an acceptable trade-off for cure of IBS symptoms
07 Mar 2022
Traditional dietary advice most preferred for IBS
Traditional dietary advice, gluten-free diet, and low FODMAP diet are all effective dietary approaches to reducing symptoms in patients with irritable bowel symptom (IBS), but traditional dietary advice is the pick of the bunch in terms of cost and convenience, according to a team of UK-based researchers.
Traditional dietary advice most preferred for IBS
07 Mar 2022
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
07 Mar 2022
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
Adding capecitabine to adjuvant chemotherapy containing docetaxel, epirubicin and cyclophosphamide significantly improves 15-year overall survival (OS) in patients with early breast cancer, results of the phase III FinXX trial (Finland Capecitabine Trial) have shown.
Adding capecitabine to adjuvant chemo improves 15-year OS in early breast cancer
07 Mar 2022
AChEI use ups lung cancer risk in older, comorbid patients
Medication with acetylcholinesterase inhibitors (AChEI) increases the risk of lung cancer among older patients and those with several comorbidities, reports a recent study.
